CA2264182A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Algos Pharmaceutical Corporation |
Anticonvulsant containing composition for treating neuropathic pain
|
WO1999008670A1
(en)
*
|
1997-08-20 |
1999-02-25 |
Guglietta, Antonio |
Gaba analogs to prevent and treat gastrointestinal damage
|
AU2002301365B2
(en)
*
|
1997-09-08 |
2005-11-24 |
Warner-Lambert Company |
Analgesic compositions comprising anti-epileptic compounds and methods of using same
|
US6593368B2
(en)
*
|
1997-09-08 |
2003-07-15 |
Warner-Lambert Company |
Analgesic compositions comprising anti-epileptic compounds and methods of using same
|
AU784225B2
(en)
*
|
1997-09-08 |
2006-02-23 |
Warner-Lambert Company |
Analgesic compositions comprising anti-epileptic compounds and methods of using same
|
WO2000002562A1
(en)
*
|
1998-07-09 |
2000-01-20 |
Warner-Lambert Company |
Compositions comprising gaba analogs and caffeine
|
US6309858B1
(en)
|
1998-09-29 |
2001-10-30 |
Syntex (U.S.A.) Llc |
T-type calcium channel variants; compositions thereof; and uses
|
ATE253556T1
(de)
|
1999-02-18 |
2003-11-15 |
Ortho Mcneil Pharm Inc |
Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes
|
JP2002538221A
(ja)
|
1999-03-10 |
2002-11-12 |
ワーナー−ランバート・カンパニー |
抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
|
DK1169060T3
(da)
*
|
1999-04-09 |
2006-01-16 |
Euro Celtique Sa |
Natriumkanalblokkerpræparater og anvendelse deraf
|
WO2001000191A2
(en)
*
|
1999-06-23 |
2001-01-04 |
Warner-Lambert Company |
Use of fosphenytion for the treatment of acute neuropathic pain
|
EP1210118B1
(de)
*
|
1999-08-20 |
2004-12-08 |
Ortho-McNeil Pharmaceutical, Inc. |
Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
|
US6573267B2
(en)
|
2000-06-30 |
2003-06-03 |
Ortho-Mcneil Pharmaceutical, Inc. |
Useful aroyl aminoacyl pyrrole compounds
|
US20040122090A1
(en)
*
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
AU2002250256B2
(en)
*
|
2001-03-08 |
2008-04-03 |
Emory University |
pH-dependent NMDA receptor antagonists
|
DE60143671D1
(de)
|
2001-06-07 |
2011-01-27 |
Sang Christine |
Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
|
ITMI20011308A1
(it)
*
|
2001-06-21 |
2002-12-21 |
Nicox Sa |
Farmaci per il dolore cronico
|
JP4350508B2
(ja)
|
2001-09-03 |
2009-10-21 |
ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー |
ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
JP2005518411A
(ja)
*
|
2002-01-16 |
2005-06-23 |
エンド ファーマシューティカルズ インコーポレーテッド |
中枢神経系の障害を治療する製薬組成物及び方法
|
JP2005525848A
(ja)
*
|
2002-02-13 |
2005-09-02 |
ベス イスラエル ディコネス メディカル センター |
血管疾患の治療方法
|
MXPA04008259A
(es)
*
|
2002-02-26 |
2005-05-27 |
Johnson & Johnson |
Co-terapia para el tratamiento de migrana que comprende derivados de un anticonvulsivo y agentes anti-migrana.
|
CA2482260A1
(en)
|
2002-04-15 |
2003-10-30 |
Beth Israel Deaconess Medical Center Inc. |
Use of heme oxygenase-1 and products of heme degradation
|
WO2004000368A1
(en)
*
|
2002-06-21 |
2003-12-31 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
|
US8637512B2
(en)
*
|
2002-07-29 |
2014-01-28 |
Glaxo Group Limited |
Formulations and method of treatment
|
CA2493301A1
(en)
*
|
2002-07-29 |
2004-02-12 |
Glaxo Group Limited |
Sustained release formulations comprising lamotrigine
|
AU2003297639A1
(en)
*
|
2002-12-02 |
2004-06-23 |
University Of Florida |
Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
|
HUP0300929A3
(en)
*
|
2003-04-09 |
2005-06-28 |
Richter Gedeon Vegyeszet |
Analgetic and/or muscle relaxant pharmaceutical composition
|
EP1638931A4
(de)
*
|
2003-06-11 |
2007-11-07 |
Neuromolecular Inc |
Verfahren zum zielgerichteten einsatz eines therapeutischen mittels
|
US20040265364A1
(en)
*
|
2003-06-25 |
2004-12-30 |
Binnur Ozturk |
Neuropathy cream
|
EP1686967A4
(de)
*
|
2003-11-25 |
2012-08-08 |
Smithkline Beecham Cork Ltd |
Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
|
WO2005072705A1
(en)
*
|
2004-01-29 |
2005-08-11 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
|
CA2556214A1
(en)
*
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
MY147767A
(en)
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
AR049646A1
(es)
*
|
2004-06-16 |
2006-08-23 |
Janssen Pharmaceutica Nv |
Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
|
US20060002999A1
(en)
*
|
2004-06-17 |
2006-01-05 |
Forest Laboratories, Inc. |
Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
|
US20060034910A1
(en)
*
|
2004-08-09 |
2006-02-16 |
Sanjay Patel |
Pharmaceutical composition for extended release of phenytoin sodium
|
ES2310366T3
(es)
*
|
2004-08-24 |
2009-01-01 |
Janssen Pharmaceutica Nv |
Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
|
NZ553970A
(en)
*
|
2004-09-10 |
2010-01-29 |
Newron Pharm Spa |
Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
|
US7619007B2
(en)
*
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
JP2008520736A
(ja)
|
2004-11-23 |
2008-06-19 |
アマダス ファーマシューティカルズ インコーポレイテッド |
持続放出コーティングまたはマトリックスおよびnmda受容体アンタゴニストを含む組成物、そのようなnmdaアンタゴニストの被験体への投与方法
|
EP2623099A1
(de)
|
2004-11-24 |
2013-08-07 |
Neuromolecular Pharmaceuticals, Inc |
Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
|
KR101406456B1
(ko)
*
|
2005-04-06 |
2014-06-20 |
아다마스 파마슈티칼스, 인코포레이티드 |
Cns 장애의 치료를 위한 방법 및 조성물
|
US20060286167A1
(en)
*
|
2005-05-02 |
2006-12-21 |
Jane Staunton |
Compositions and methods for the treatment of neurodegenerative diseases
|
WO2006122035A2
(en)
*
|
2005-05-06 |
2006-11-16 |
University Of Maryland, Baltimore |
Method for treating central pain syndrome or for inducing centrally generated pain in an animal model
|
JP2008545650A
(ja)
|
2005-05-20 |
2008-12-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
スルファミド誘導体の製造方法
|
US8975298B2
(en)
|
2005-06-27 |
2015-03-10 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for pain
|
AR058389A1
(es)
|
2005-12-19 |
2008-01-30 |
Janssen Pharmaceutica Nv |
Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
|
US8937096B2
(en)
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US8497298B2
(en)
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US8716231B2
(en)
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8691867B2
(en)
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
KR101380137B1
(ko)
*
|
2005-12-22 |
2014-04-11 |
뉴론 파마슈티칼즈 에스. 피. 에이. |
칼슘 및/또는 나트륨 채널 조절제로서 2-페닐에틸아미노유도체
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
US20070191449A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
|
US20070191461A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
|
US20070191452A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
|
WO2007120485A2
(en)
*
|
2006-03-30 |
2007-10-25 |
Cinergen, Llc |
Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
|
EP2026790A2
(de)
|
2006-05-19 |
2009-02-25 |
Janssen Pharmaceutica, N.V. |
Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
|
WO2008079728A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Allergan, Inc. |
Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
US20120083508A1
(en)
|
2006-12-22 |
2012-04-05 |
Allergan, Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
CN103497114A
(zh)
*
|
2007-06-29 |
2014-01-08 |
埃莫里大学 |
用于神经保护的nmda受体拮抗剂
|
ES2416723T3
(es)
*
|
2007-10-09 |
2013-08-02 |
Merck Patent Gmbh |
Composiciones farmacéuticas que contienen benfotiamina y gabapentina
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
US20090247616A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
|
US20090247644A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Forest Laboratories Holdings Limited |
Memantine formulations
|
AU2009271362B2
(en)
|
2008-06-23 |
2014-03-13 |
Janssen Pharmaceutica Nv |
Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
|
US8815939B2
(en)
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
CA2738468A1
(en)
|
2008-09-27 |
2010-04-01 |
Taraxos Inc. |
Topical formulations for treatment of neuropathy
|
BR112012013487A2
(pt)
|
2009-12-02 |
2017-10-03 |
Adamas Pharmaceuticals Inc |
Composições de amantadina e métodos de uso
|
WO2011127235A1
(en)
|
2010-04-07 |
2011-10-13 |
Eisai Inc. |
Combination therapy for the treatment of dementia
|
FR2998892B1
(fr)
|
2012-12-04 |
2015-01-02 |
Pf Medicament |
Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
US10272097B2
(en)
|
2013-12-24 |
2019-04-30 |
Virginia Commonwealth University |
Uses of oxygenated cholesterol sulfates (OCS)
|
UA125040C2
(uk)
|
2016-12-06 |
2021-12-29 |
Топікал Інновейшнс Б.В. |
Фенітоїн для місцевого застосування для використання при лікуванні периферичного нейропатичного болю
|
WO2018106108A1
(en)
|
2016-12-06 |
2018-06-14 |
KEPPEL HESSELING, Jan Marius |
Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
|
KR20210002472A
(ko)
*
|
2018-04-16 |
2021-01-08 |
바이오젠 엠에이 인코포레이티드 |
신경병증성 통증을 치료하는 방법
|
WO2020054872A1
(ja)
*
|
2018-09-14 |
2020-03-19 |
国立大学法人富山大学 |
急性帯状疱疹痛の治療剤
|
WO2021220284A1
(en)
|
2020-05-01 |
2021-11-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
|
WO2022113069A1
(en)
|
2020-11-24 |
2022-06-02 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
|
US11977085B1
(en)
|
2023-09-05 |
2024-05-07 |
Elan Ehrlich |
Date rape drug detection device and method of using same
|